USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A recent Mercer survey reveals that over half of large employers plan to shift more health care costs to employees amid rising expenses expected in 2026.

Understanding the gut-brain axis is key to addressing eating disorders. This study highlights microbiota's influence and ...